Impact of managed care on the treatment of atrial fibrillation

American Journal of Cardiology

Volumn 81, Issue 5 A, 1998, Pages 30C-34C

  Pratt, Craig M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; CLINICAL PROTOCOL; CONFERENCE PAPER; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HEART ATRIUM FIBRILLATION; HUMAN; MANAGED CARE; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0032510389     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00184-2     Document Type: Conference Paper

References (21)

1. Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992;326: 1264-1271.
2. Prystowsky EN, Benson W, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse G. Management of patients with atrial fibrillation. A statement of healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 1996;93: 1262-1277.
3. Pritchett EL, DaTorre SD, Platt ML, McCarville SE, Hougham AJ for the Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. J Am Coll Cordial 1991;17:297-303.
4. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett EL. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80:1557-1570.
5. Chimienti M, Cullen MT, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J 1995;16:1943-1951.
6. Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol 1996;77: 66A-71A.
7. Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991; 114:539-544.
8. Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: A dangerous imbalance in the risk-benefit ratio. Am Heart J 1989;118:433-440.
9. Pratt CM, Brater CD, Harrell FE, Kowey PR, Leier CV, Lowenthal DT, Messerli FH, Packer M, Pritchett ELC, Ruskin JN. Clinical and regulatory implications of the Cardiac Arrhythmia Suppression Trial (CAST). Am J Cardiol 1990;65:103-105.
10. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results of randomized controlled trials. JAMA 1993;270:1589-1595.
11. The planning and steering committees of the AFFIRM study for the NHLBI AFFIRM investigators. Atrial fibrillation follow-up investigation of rhythm management: The AFFIRM study design. Am J Cardiol 1997;79:1198-1202.
12. CHF STAT Investigators. Veterans Affairs congestive heart failure antiarrhythmic trial. Am J Cardiol 1993;72:99F-102F.
13. Julian DG, Camm AJ, Fragin G, Janse MJ, Munoz A, Schwartz PJ, Simon P for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74.
14. Cairns JA, Connolly SJ, Robert R, Gent M for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-682.
15. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
16. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
17. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991;84:527-539.
18. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
19. Kobrin I, Charlon V. Predictable clinical effects in the treatment of hypertension and chronic stable angina pectoris: clinical studies of mibefradil. J Hypertens 1997;15:S35-S40.
20. Bakx AL, van der Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo controlled study. Am Heart J 1995;130:748-757.
21. Braun S, van der Wall EE, Emanuelsson H, Korbin I. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol 1996;27:317-322.